Lupin is currently trading at Rs 1525.10, up by 4.00 points or 0.26% from its previous closing of Rs 1521.10 on the BSE.
The scrip opened at Rs 1532.00 and has touched a high and low of Rs 1534.00 and Rs 1509.00 respectively. So far 47349 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs 1,599.00 and Rs 1505.00 respectively. The current market cap of the company is Rs. 68821.97 crore.
The promoters holding in the company stood at 46.76%, while Institutions and Non-Institutions held 42.40% and 10.83% respectively.
Lupin’s US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. has received final approval for its Linezolid Tablets, 600 mg from the United States Food and Drug Administration (FDA) to market a generic equivalent of Pharmacia & Upjohn Company's Zyvox Tablets, 600 mg.
Linezolid Tablets, 600 mg are the AB rated generic equivalent of Pharmacia & Upjohn Company's Zyvox Tablets, 600 mg. It is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria. Zyvox Tablets had US sales of $ 273.6 million as per IMS MAT June 2016 data.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.
